Imagine a game of chess where your opponent's king is in check. It cannot move, but the game is not over—the piece remains on ...
Findings identify genes that may represent possible new targets for a "block and lock" strategy for curing HIV.
Since the HIV epidemic began, the diagnosis of HIV has evolved from a death sentence to a chronic, but manageable condition by starting and staying on treatment. HIV treatment can help people live ...
For millions of people living with HIV, a daily regimen of medications is a lifelong necessity. If they stop taking the drugs ...
Addressing the question of whether and how immune cells (macrophages) in the central nervous system (CNS) traffic out, researchers have now identified a perineural pathway through which the HIV virus ...
A new single-pill HIV treatment has proved as effective as regimens of up to 11 tablets a day in suppressing the virus in hard-to-treat patients. It’s “a potential breakthrough for a growing cohort of ...
Study finds long-acting injectable therapy significantly reduces treatment failure compared to standard oral medicationA new ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment ...
Long-acting CAB+RPV is preferred by patients for ART due to reduced dosing frequency and stigma, with 89% switching after viral suppression. Studies like PILLAR and EBONI confirm the effectiveness and ...
High stigma levels correlate with lower ART adherence and viral suppression in women with HIV, especially those who inject drugs. The study used data from the WIHS, focusing on stigma's impact on HIV ...
SPOKANE, Wash. – The FDA has approved a twice-yearly injection for HIV prevention following a groundbreaking clinical trial. Years before the approval, Dr. Rachel Safran was part of an original ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results